Supplier
Advance Health RX INC
Advance Health RX INC was paid $239K by Medicaid between Jun 2022 and Dec 2024, across 11 billing codes. Its largest line is A4238, Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service — 86% of everything it billed.
33Billing provider infoADVANCE HEALTH RX INC
BRONX, NY 10458
BRONX, NY 10458
33aNPI1871166389assigned 07/22/2021
33bProvider typeCommunity/Retail Pharmacy
28Total paid$239K
24GClaims1,847
24DCodes billed11
24AFirst – last monthJun 2022 – Dec 2024
Compared with peers
Next to other Community/Retail Pharmacy providers in New York
Rank by total paid#19 of 129
Median peer was paid$2K
This provider vs. median117×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 635 | $5K | |
| 2023 | 120 | $4K | |
| 2024incomplete | 1,092 | $229K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A4238 | Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 86% | 791 | 789 | $206K |
| A4239 | Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 11% | 421 | 420 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 143 | 135 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 42 | 41 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 22 | 22 | $646.80 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 126 | 117 | $125.51 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 102 | 94 | $53.99 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 79 | 74 | $30.53 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 43 | 43 | $15.26 |
| 99051 | <1% | 35 | 34 | $7.00 | |
| 99000 | 0% | 43 | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZAVLYANOV, MOYSEY (OWNER)